Advertisement.

ALT Projected Dividend Yield

Altimmune Inc ( NASDAQ : ALT )

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.

20 YEAR PERFORMANCE RESULTS

ALT Dividend History Detail
ALT Dividend News
ALT Competitors News

# of Shares: 0

Closing Price: 9.03

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
2026	0.00	0%	0	$ 0.00	0.00%
2027	0.00	0%	0	$ 0.00	0.00%
2028	0.00	0%	0	$ 0.00	0.00%
2029	0.00	0%	0	$ 0.00	0.00%
2030	0.00	0%	0	$ 0.00	0.00%
2031	0.00	0%	0	$ 0.00	0.00%
2032	0.00	0%	0	$ 0.00	0.00%
2033	0.00	0%	0	$ 0.00	0.00%
2034	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000